Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 34
GLP-1 Receptor Agonists and Sleep Apnea
Tirzepatide holds a US FDA approval for sleep apnea backed by SURMOUNT-OSA data. Here is what the evidence supports for the GLP-1 receptor agonist class.
Insulin resistance to incretin agonism: T2D
A 2026 review maps the path from insulin resistance to T2DM prevention, covering metformin, GLP-1 agonists, tirzepatide, and retatrutide.
Semaglutide mouse lifespan: what we know
A 2026 Nature study found semaglutide extended lifespan in older female mice by ~100 days. Here is what the finding means, and what it does not.
Semaglutide, obesity, and chronic migraine
A 2026 letter in Headache argues semaglutide may break a loop in which obesity worsens migraine and fasting-driven avoidance triggers more attacks.
How labs verify semaglutide in the pen
A 2026 J. Chromatography B review maps analytical methods for semaglutide in pharmaceutical formulations and plasma.
Semaglutide oral bioavailability explained
Oral semaglutide achieves 0.4% to 1% bioavailability versus 89% for the injection. A 2026 review in Pharmaceutical Research explains the barriers.
Semaglutide extended lifespan in old mice
A Nature study found late-life semaglutide extended median lifespan by 12% in aged female mice, which is not proof the drug slows aging in people.
Semaglutide's direct reproductive effects
A 2026 rat study found semaglutide affects gonads beyond weight loss: androgens protected in males, reproductive hormones reduced in females.
GLP-1 drugs and skin disease: the evidence
A 2026 dermatology review examines how GLP-1 receptor agonists, including tirzepatide, may affect psoriasis, hidradenitis suppurativa, acne, and wound healing.
GLP-1 Drugs and Pregnancy: A Trends Update
Real-world data show a gap between guideline recommendations and GLP-1 discontinuation timing around pregnancy. Here is what the evidence says.
Incretin drugs: outcomes before weight loss
A 2026 review ranks incretin therapies by CV mortality evidence first, weight loss second, and maps drug choice to patient phenotype via receptor pharmacology.
Lilly and the Medicare GLP-1 bridge program
The Medicare GLP-1 Bridge launched July 2026 at a $50 monthly copay. Lilly's Q2 numbers show the scale analysts are mapping against it.